158 related articles for article (PubMed ID: 38011864)
1. Management of Brain Metastases: A Review of Novel Therapies.
Bellur S; Khosla AA; Ozair A; Kotecha R; McDermott MW; Ahluwalia MS
Semin Neurol; 2023 Dec; 43(6):845-858. PubMed ID: 38011864
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Therapy for Cancer Metastasis to the Brain.
Franchino F; Rudà R; Soffietti R
Front Oncol; 2018; 8():161. PubMed ID: 29881714
[TBL] [Abstract][Full Text] [Related]
3. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
5. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
9. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
Khandekar MJ; Piotrowska Z; Willers H; Sequist LV
Oncologist; 2018 Sep; 23(9):1054-1062. PubMed ID: 29703765
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
Long GV; Margolin KA
Am Soc Clin Oncol Educ Book; 2013; ():393-8. PubMed ID: 23714558
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic options for brain metastases].
Preusser M; Winkler F
Nervenarzt; 2015 Jun; 86(6):716-8. PubMed ID: 25989738
[TBL] [Abstract][Full Text] [Related]
12. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
14. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
15. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
[TBL] [Abstract][Full Text] [Related]
16. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
Wrona A; Dziadziuszko R; Jassem J
Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
[TBL] [Abstract][Full Text] [Related]
17. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
[TBL] [Abstract][Full Text] [Related]
19. [Radiation therapy and targeted therapies: Risks and opportunities].
Nicolas E; Lucia F
Cancer Radiother; 2022 Oct; 26(6-7):973-978. PubMed ID: 36057520
[TBL] [Abstract][Full Text] [Related]
20. [Cancer Therapy Targeting Fusion Genes in Lung Cancer].
Tateishi A; Goto Y
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1043-1047. PubMed ID: 36281592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
